1610804-86-8

Basic information

• Product Name: N-(2-((1-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-2-methoxybenzamide
• Synonyms: N-(2-((1-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-2-methoxybenzamide
• CAS NO: 1610804-86-8
• Molecular Weight: 619.72
• Mol File: 1610804-86-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-(2-((1-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-2-methoxybenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-((1-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-2-methoxybenzamide(1610804-86-8)
• EPA Substance Registry System: N-(2-((1-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-2-methoxybenzamide(1610804-86-8)

Safety Data

• Hazardous Substances Data: 1610804-86-8(Hazardous Substances Data)

Upstream product

• 52536-39-7 2-(prop-2-ynyloxy)benzenediazonium tetrafluoroborate 
• 13350-09-9 1-nitro-2-(prop-2-yn-1-yloxy)benzene 
• 82925-02-8 4-<2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolyl)ethyl>benzenamine 
• 82925-01-7 1,2,3,4-Tetrahydro-6,7-dimethoxy-2-[2-(4-nitrophenyl)ethyl]-isoquinoline 
• 5339-26-4 (4-nitrophenyl)ethyl bromide 
• 2328-12-3 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline monohydrochloride 
• 1610805-21-4 C₁₇H₁₅NO₃ 
• 1610805-19-0 2-(2-(4-azidophenyl)ethyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 
• 88-75-5 2-hydroxynitrobenzene 

Relevant articles and documents

Discovery of novel P-glycoprotein-mediated multidrug resistance inhibitors bearing triazole core via click chemistry

A novel series of P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) inhibitors bearing a triazol-phenethyl-tetrahydroisoquinoline scaffold were designed and synthesized via click chemistry. Most of the synthesized compounds showed higher reversal activity than verapamil (VRP). Among them, the most potent compound 5 showed a comparable activity with the known potent P-gp inhibitor WK-X-34 with lower cytotoxicity (IC50s > 100 μm). Compared with VRP, compound 5 exhibited more potency in increasing drug accumulation in K562/A02 MDR cells. Moreover, compound 5 persisted longer chemo-sensitizing effect (>24 h) than VRP (6 h) with reversibility. Given the low intrinsic cytotoxicity and the potent reversal activity, compound 5 may represent a promising candidate for developing P-gp-mediated MDR inhibitor.